Doyle Anthony
SEC CIK 1808688 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | CFO | 380.3K | $642.2K | $62.1K | 12 | 2021-11-23 | 2024-12-19 |
Most active insiders at BCRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Barnes Alane P | CLO | — | $3.46M |
| 2 | HEGGIE THERESA | Dir | — | $504.8K |
| 3 | McKee Amy E | Dir | — | $100.3K |
| 4 | SANDERS MACHELLE | Dir | — | $68.5K |
| 5 | Menon Sandeep | Chief R, D Off | — | — |
| 6 | Ghias Babar | CFO | — | — |
| 7 | Gayer Charles K | Pres, CCO | — | — |
| 8 | Milne Jill C. | Dir | — | — |
| 9 | Frank Steven | Dir | — | — |
| 10 | Galson Steven K | Dir | — | — |
Doyle Anthony made no open-market trades at BCRX in the last 12 months.
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-23 | 2024-12-19 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | A - Grant | $0.00 | +120.7K | 380.3K | +46% | $0 |
| D | 2024-12-23 | 2024-12-19 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | F - Tax | $7.39 | -2,461 | 377.9K | -0.6% | -$18.2K |
| 2024-12-17 | 2024-12-14 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | F - Tax | $7.53 | -7,890 | 259.6K | -3% | -$59.4K | |
| 2024-05-15 | 2024-05-14 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | P - Purchase | $5.57 | +36.3K | 266.7K | +16% | +$202.2K | |
| 2023-12-20 | 2023-12-19 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | F - Tax | $6.05 | -2,482 | 227.4K | -1% | -$15.0K | |
| D | 2023-12-18 | 2023-12-14 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | A - Grant | $0.00 | +34.0K | 235.4K | +17% | $0 |
| D | 2023-12-18 | 2023-12-14 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | F - Tax | $6.43 | -5,475 | 229.9K | -2% | -$35.2K |
| D | 2022-12-21 | 2022-12-19 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | A - Grant | $0.00 | +34.0K | 198.0K | +21% | $0 |
| 2022-12-19 | 2022-12-15 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | S - Sale | $10.90 | -5,700 | 164.0K | -3% | -$62.1K | |
| A | 2022-01-13 | 2021-12-14 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | A - Grant | $0.00 | +75.0K | 168.7K | +80% | $0 |
| D | 2021-12-16 | 2021-12-14 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | A - Grant | $0.00 | +115.0K | 208.7K | +123% | $0 |
| 2021-11-24 | 2021-11-23 | BCRX | BIOCRYST PHARMACEUTICALS INC | Doyle Anthony | CFO | P - Purchase | $12.48 | +35.3K | 93.7K | +60% | +$440.0K |
Purchase Sale Sale after option exercise All abbreviations